Value of Cancer Immunotherapy Summit
Organized in collaboration with the American Society of Clinical Oncology (ASCO)

Sunday, November 13, 201
Non CE-sessions

Co-Chairs:
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Lowell E. Schnipper, MD – Beth Israel Deaconess Medical Center
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute

7:45 – 7:50 a.m.       Annual Meeting Organizer Welcome
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institute of Health

7:50 – 8:00 a.m.       Program Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 – 8:30 a.m.        Evaluation of Current Value Models
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute

8:30 – 8:45 a.m.        Cancer Immunotherapy Perspective on Current Value Models
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center

8:45 – 9:05 a.m.        Economic Outcomes of Cancer Therapy: ISPOR Initiatives on U.S. Value Assessment Framework
Lou Garrison, PhD, AB – University of Washington

9:05 – 9:25 a.m.        Patient Perspective
Steven Silverstein, MBA – Melanoma Research Foundation

9:25 – 9:45 a.m.        Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute

9:45 – 10:10 a.m.       Panel Discussion
Moderator:
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey

Panelists:
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Lou Garrison, PhD, AB – University of Washington
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute
Steven Silverstein, MBA – Melanoma Research Foundation
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute
Session II: Perspectives on the Value of Cancer Immunotherapy

10:10 – 10:30 a.m.  Payor Perspective
William McGivney, PhD – McGivney Global Advisors

10:30 – 10:50 a.m.  Industry Perspective
Jon M. Wigginton, MD – MacroGenics, Inc.

10:50 – 11:10 a.m.  Predictive and Companion Biomarkers
Roy S. Herbst, MD, PhD – Yale Cancer Center

11:10 – 11:55 a.m.  Panel Discussion
Moderator:
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center

Panelists:
Kirsten Axelsen, MS – Pfizer
Daniel S. Chen, MD, PhD – Genentech
Ravinder Dhawan, PhD – Merck & Co
Roy S. Herbst, MD, PhD – Yale Cancer Center
Gregory Keenan, MD – AstraZeneca
William McGivney, PhD – McGivney Global Advisors
Jon M. Wigginton, MD – MacroGenics, Inc.

11:55 – noon  Closing Remarks